文献速递类风湿关节炎

基线侵蚀与ACPA共存对类风湿关节炎疾病活动度的影响:METEOR登记研究

Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry.
PubMed 文献 · RMD Open · 2019-07-30

基于国际METEOR登记中初诊类风湿关节炎患者的真实世界数据,按基线ACPA和侵蚀状态分为四组,分析6或12个月内DAS和HAQ变化及治疗生存。四组间DAS和HAQ变化有统计学差异但临床意义不大,ACPA-/侵蚀-组治疗切换可能性低于ACPA+/侵蚀-参考组。

要点

  • ACPA和侵蚀状态四组间DAS和HAQ变化虽有统计学差异,但分层后差异小且无临床意义。
  • ACPA-/侵蚀-组较ACPA+/侵蚀-参考组更少切换治疗(p<0.001)。
  • 随访6或12个月内各组对初始治疗反应相似,ACPA-/侵蚀-组第一年治疗切换可能性更低。

核心结论

  • ACPA和侵蚀状态四组间DAS和HAQ变化有统计学显著差异,但分层后差异小且无临床意义。
  • 随访6或12个月内各组对初始DMARD治疗反应相似,但ACPA-/侵蚀-组第一年治疗切换可能性更低。

研究设计与样本

  • 国际METEOR登记中初诊类风湿关节炎患者的真实世界数据。
  • 按基线ACPA和侵蚀状态分为四组:ACPA-/侵蚀-(701例)、ACPA-/侵蚀+(334例)、ACPA+/侵蚀-(1585例)、ACPA+/侵蚀+(1993例)。
  • 采用线性混合模型评估最长6或12个月内DAS和HAQ变化,采用多重失败时间Cox回归评估治疗生存。

主要发现

  • 四组间DAS和HAQ随时间变化在最长随访6和12个月后均有统计学显著差异,但分层后差异小且无临床意义。
  • ACPA-/侵蚀-组较ACPA+/侵蚀-参考组更少切换治疗(p<0.001)。
  • 其他两个ACPA/侵蚀组与参考组无差异。

临床怎么用

  • 基线ACPA和侵蚀状态共存对初始DMARD治疗反应的影响临床意义有限,各组反应相似。
  • ACPA-/侵蚀-患者第一年治疗切换可能性较低,可据此评估治疗稳定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate associations between baseline presence of erosions and/or anti-citrullinated protein antibodies (ACPA) on functional ability, disease activity and treatment survival over time. METHODS: Real life data from newly diagnosed rheumatoid arthritis patients were identified in the international METEOR registry. Patients were grouped according to presence/absence of ACPA and/or erosions at baseline. Associations between the presence of ACPA and/or erosions (four groups) with the change of Disease Activity Score (DAS) and Health Assessment Questionnaire (HAQ) over time were assessed using linear mixed models during maximum 6 or maximum 12 months from baseline. Treatment survival was assessed using multiple failure-times Cox regression. RESULTS: Data were included from 701 ACPA‒/erosions‒, 334 ACPA‒/erosions+, 1585 ACPA+/erosions‒ and 1993 ACPA+/erosions+ patients. We found statistically significant differences in DAS and HAQ change over time between the four groups, both after maximum follow-up durations of 6 and of 12 months, but after stratification differences proved small and not clinically meaningful. Patients in the ACPA‒/erosions‒ group were less likely to switch treatment compared with the ACPA+/erosions‒ reference group (p<0.001). The other two ACPA/erosions groups did not differ from the reference group. CONCLUSIONS: In this analysis of worldwide real life data, we found statistically significant, but clinically irrelevant differences in treatment response to initial disease modifying anti-rheumatic drug therapies as measured by DAS and HAQ in ACPA‒/erosions‒, ACPA‒/erosions+, ACPA+/erosions‒ and ACPA+/erosions+ rheumatoid arthritis patients. However, after maximum follow-up durations of 6 and 12 months all groups had a similar response to initial treatment, but with a lower likelihood to switch treatment for ACPA‒/erosions‒ patients during the first year of follow-up.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Bergstra SA, Couto MC, Govind N, et al. Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry. RMD Open. 2019. PMID: 31413867. doi:10.1136/rmdopen-2019-000969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。